Although neutralization of IFN-γ has shown efficacy in mouse models (64), anti-IFN-γ (fontolizumab) trials for CD showed poor clinical efficacy and were discontinued (84), but a combined inhibition across IFN types or together with anti-TNFα may be worthy of consideration. Here, IFNA1 is linked to Cowden disease.